1. Home
  2. GKOS vs LPX Comparison

GKOS vs LPX Comparison

Compare GKOS & LPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.56

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Logo Louisiana-Pacific Corporation

LPX

Louisiana-Pacific Corporation

HOLD

Current Price

$75.05

Market Cap

4.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
LPX
Founded
1998
1973
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Forest Products
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
4.9B
IPO Year
2015
1994

Fundamental Metrics

Financial Performance
Metric
GKOS
LPX
Price
$116.56
$75.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
6
Target Price
$133.07
$107.17
AVG Volume (30 Days)
661.7K
663.4K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
1.58%
EPS Growth
N/A
N/A
EPS
N/A
2.08
Revenue
$507,442,000.00
$2,708,000,000.00
Revenue This Year
$23.30
N/A
Revenue Next Year
$27.43
$11.66
P/E Ratio
N/A
$36.55
Revenue Growth
32.33
N/A
52 Week Low
$73.16
$69.34
52 Week High
$130.23
$102.86

Technical Indicators

Market Signals
Indicator
GKOS
LPX
Relative Strength Index (RSI) 58.27 49.36
Support Level $104.72 $74.00
Resistance Level $123.16 $75.69
Average True Range (ATR) 4.70 2.64
MACD 1.71 0.87
Stochastic Oscillator 69.51 77.70

Price Performance

Historical Comparison
GKOS
LPX

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About LPX Louisiana-Pacific Corporation

Louisiana-Pacific Corp is an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The Siding business of the company serves different markets with a broad product portfolio of engineered wood siding, trim, soffit, and fascia. The Company operates through three operating segments: Siding, OSB, and LP South America (LPSA). The company generates majority of its revenue from siding segment.

Share on Social Networks: